Voyager Therapeutics, Inc. stays a Strong Buy as its dual Alzheimer’s programs near key 2026-2027 catalysts. Click for this ...
A single AAV injection carrying the leptin gene normalised fasting insulin and fully reversed hepatic triglyceride ...
Five poster presentations will highlight exciting progress in AskBio’s adeno-associated virus (AAV) manufacturing ...
PAK BioSolutions today announced the publication of a peer-reviewed study on integrated, continuous purification of adeno-associated virus serotype 8 (AAV8) using the PAK PD™ Process Development Scale ...
Arbor Biotechnologies, Inc., a biotechnology company discovering and developing the next generation of genetic medicines, ...
Hamburg congress, Neurogene will present preclinical gene-regulation findings and early-response observations from the ...
Solid Biosciences Inc. announced that seven abstracts have been accepted for poster presentation at the 33rd European Society of Gene & Cell Therapy (ESGCT) Annual Congress, taking place October 27-30 ...
Estuary Biotherapeutics launched with $103M to deliver AAV gene therapy locally to the kidney for ADPKD — the delivery technology, not the gene science, is the real breakthrough.
Latus Bio has developed an experimental gene-delivery technology that achieved approximately five times greater kidney uptake ...
Adeno-associated virus (AAV) vectors have become the delivery vehicle of choice for modern gene therapy, carrying therapeutic ...
In recent months, news came out about several distressing cases that have underscored the risks of gene therapy, which ...
Genezen, a gene therapy contract development and manufacturing organization (CDMO), and Galibra Neuroscience, a biotechnology ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results